Myocarditis in the Elderly against the Background of Covid-19: Clinical Features and Drug Treatment Tactics
DOI:
https://doi.org/10.51699/ijhsms.v2i4.1420Keywords:
COVID-19, SARS-CoV-2, myocarditis, myocardial damage, cardiovascular system, clinical manifestations, treatment, drug effectsAbstract
Myocarditis associated with novel coronavirus infection (COVID-19) is a difficult diagnosis from all points of view. The clinical manifestations of this pathology may be nonspecific or erased; while it’s long-term consequences for the patient are unknown. Diagnostic approaches are complex and practically impossible in covid clinics. Therapy carried out in patients with COVID-19 carries a potential threat to the myocardium.
The aim of this review was to summarize the information available to date on the clinical aspects and medical treatment of inflammatory myocardial injury in COVID-19. More than 300 relevant literature sources have been analyzed, and the most significant information in the light of the problem under discussion is given in the article.
The results of the analysis of the current world literature have shown convincing evidence of the possible development of myocarditis as part of a new coronavirus infection. Histological verification of myocardial damage associated with COVID-19 presents significant difficulties, since end omyocardial biopsy is not always possible in conditions of severe infection. In this regard, the statistics do not reflect complete information on the prevalence of myocarditis associated with COVID-19. Due to insufficient knowledge of the pathogenesis of inflammatory myocardial damage, drug approaches have not been developed and are mainly empirical in nature. Due to the ambiguity of the prognosis of patients with myocarditis associated with COVID-19, further study of the problem is required.
Downloads
References
Dominguez F., Kuhl U., Pieske B. et al. Update on myocarditis and inflammatory cardiomyopathy: reemergence of endomyocardial biopsy. Rev Esp Cardiol. 2016; 69:178–187. DOI: 10.1016/j.recesp.2015.10.018.
Clinical recommendations. Diagnosis and treatment of myocarditis. 2020 (Electronic resource.) URL: http://www.scardio.ru/content/Guidelines/2020/Clinic_rekom_Miocardit.pdf (accessed: 09.10.2021). [Clinical guidelines. Diagnosis and treatment of myocarditis. 2020 (Electronic resource.) URL: http://www.scardio.ru/content/Guidelines/2020/Clinic_rekom_Myokardit.pdf (access date: 09.10.2021) (in Russ.)].
Xiong TY, Redwood S., Prendergast B., Chen M. Coronaviruses and the cardiovascular system: acute and longterm implications. Eur Heart J. 2020;2:1–3. DOI: 10.1093/eurheartj/ehaa231.
Chen L., Li X., Chen M. et al. The ACE2 expression in human heart indicates a new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020; 116:1097–1100. DOI: 10.1093/cvr/cvaa078.
Kawakami R., Sakamoto A., Kawai K. et al. Pathological evidence for SARS-CoV-2 as a cause of myocarditis: JACC Review Topic of the Week. J Am Call Cardiol. 2021;77(3):314–325. DOI: 10.1016/j.jacc.2020.11.031.
Wenzhong L., Hualan L. COVID-19: Attacks the 1-Beta Chain of Hemoglobin and Captures the Porphyrin to Inhibit Human Heme Metabolism (Electronic resource.) URL: https://chemrxiv.org/engage/chemrxiv/article -details/60c74fa50f50db305139743d (access date: 10/15/2021). DOI: 10.26434/chemrxiv.11938173.v8.
Verdecchia P., Cavallini C., Spanevello A., Angeli F. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Eur J Intern Med. 2020; 76:14–20. DOI: 10.1016/j.ejim.2020.04.037.
Driggin E., Madhavan MV, Bikdeli B. et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Call Cardiol. 2020; 75(18):2352–2371. DOI: 10.1016/j.jacc.2020.03.031.
Long B., Brady WJ, Koyfman A. et al. Cardiovascular complications in COVID-19. Am J Emerge Med. 2020; 18:1–4. DOI: 10.1016/j.ajem.2020.04.048.
Ho JS, Sia CH, Chan MY et al. Coronavirus-induced myocarditis: A meta-summary of cases. Heart Lung. 2020; 49(6):681–685. DOI: 10.1016/j.hrtlng.2020.08.013.
Kariyana PT, Sutarjono B., Grewal E. et al. A Systematic Review of COVID-19 and Myocarditis. Am J Med Case Rep. 2020;8(9):299–305. DOI: 10.12691/ajmcr-8-9-11.
Practice of echocardiography during the COVID-19 pandemic: guidance from the Canadian Society of Echocardiography (Electronic resource.) URL: http://csecho.ca/wp-content/uploads/2020/03/CSE-COVID-19- Guidance_English-1.pdf (access date: 10/15/2021).
Wichmann D., Sperhake JP, Lütgehetmann M. et al. Autopsy Findings and Venous Thromboembolism in Patients with COVID-19: A Prospective Cohort Study. Ann Intern Med. 2020; 173(4):268–277. DOI: 10.7326/M20-2003.
Ruan Q., Yang K., Wang W. et al. Correction to: Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan. China Intens Care Med. 2020;6:1–4. DOI: 10.1007/s00134-020-06028-z.
Caforio AL, Pankuweit S., Arbustini E. et al. European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34(33):2636–2648. DOI: 10.1093/eurheartj/eht210.
Naimov Dilshod. ASSESSMENT OF WOMEN'S OPINION ON THE RISK OF OVERWEIGHT AND OBESITY. SYNERGY: JOURNAL OF ETHICS AND GOVERNANCE Volume: 01 Issue: 06 | 2021
MEDICAL THERAPY IN PATIENTS WITH ACUTE HEART FAILURE Naimov DK EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE Vol. 2 no. 5 (2022) EJMMP ISSN: 2795-921X
Rakhmatova D.B.// "Main" symptoms and leading clinical variants of the course of acute coronary syndrome in women.//D.B. Rakhmatova. Journal of Biomedicine and Practice 2019, vol. 2, issue 6, pp. 68-73. http://dx.doi.org/10.26739/2181-9300-2019-6-8
DK NaimovLEFT VENTRICULAR HYPERTROPHY: DIAGNOSIS IN 40-60-YEAR-OLD WOMEN WITH HYPERTENSION.
Naimov Dilshod.ASSESSMENT OF WOMEN'S OPINION ON THE RISK OF OVERWEIGHT AND OBESITYVol. 1 no. 6 (2021): SYNERGY: JOURNAL OF ETHICS AND GOVERNANCE
DKNaimov. (2022). MYOCARDITIS AGAINST THE BACKGROUND OF COVID-19: CLINICAL FEATURES AND DRUG TREATMENT. Journal of Integrated Education and Research, 1(1), 497–512.
DK Naimov MEDICAL THERAPY IN PATIENTS WITH ACUTE HEART FAILURE
Kalenchyts T.I., Rysevets A.V., Antanovich Zh.V. Perenosimost' fizicheskih training u
Naimov DK (2022). LEFT VENTRICULAR HYPERTROPHY: DIAGNOSIS IN 40-60-YEAR-OLD WOMEN WITH HYPERTENSION. European Journal of Interdisciplinary Research and Development, 4, 186–188. Retrieved
Fromhttp://www.ejird.journalspark.org/index.php/ejird/article/view/86
Smichek VB Reabilitatsiya bol'nih i invalidov [Rehabilitation of patients and invalids].
Moscow: MedLit, 2010, 560 p. (in Russian).
Naimov DK (2022). LEFT VENTRICULAR HYPERTROPHY: DIAGNOSIS IN 40-60-YEAR-OLD WOMEN WITH HYPERTENSION. European Journal of Interdisciplinary Research and Development, 4, 186–188.
